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Contemporary presentation and evolution of management of 41 neck
paragangliomas
Stavros K. Kakkos, Daniel J. Reddy, Alexander D. Shepard, Judith C. Lin,
Timothy J. Nypaver, Mitchell R. Weaver
Background: The aim of the present study was to review the contemporary
presentation and evolution of management of neck paragangliomas.
Methods: Forty-one neck paragangliomas operated on in 36 patients over
a 44 year period were included in the current report. The study period
was divided into two parts, the first three decades (1964-1989), during which
the current management techniques were evolved, and the last two decades
(1990-2008).
Results: Patients presented with a palpable neck mass (n Z 17), cranial
nerve (CN) palsy (n Z 3) or both (n Z 6), or the lesion was an incidental
finding (n Z 14). The use of cross-section imaging modalities (n Z 24)
increased from 35% during the first part of the study to 95% during the second
part of the study (P < .001). Preoperative embolization (introduced in 1979)
was performed in 60% (median size 4.3 cm for embolized vs 3 cm [PZ .02],
for non-embolized tumors). During the first study period, the frequency of
Shamblin group II/III tumors was 95% compared with a frequency of 42%
during the second study period (P < .001, odds ratio 25), median blood loss
was 600 ml and 150 ml, respectively (PZ .001) and the transfusion rate was
44% and 5%, respectively (PZ .008). The incidence of temporary and perma-
nent new CN deficits postoperatively was 22.5% and 10%, respectively, and
was similar during the two study periods. Three tumors were malignant,
based on lymph node involvement (n Z 1) or development of late metas-
tases (n Z 2).
Conclusions: In the modern era, neck paragangliomas can be managed with
a low incidence of long-term sequelae. Smaller, asymptomatic, and inci-
dentally detected tumors are currently the most common presentation
pattern.
Renal artery revascularization: Outcomes stratified by indication for
intervention
Virendra I. Patel, Mark F. Conrad, Christopher J. Kwolek, Glenn M.
LaMuraglia, Thomas K. Chung, Richard P. Cambria
Objectives: Application of endovascular therapy has led to increasing
rates of renal artery intervention with unclear effect on hypertension
(HTN) and/or renal salvage (RS). We evaluated the role of procedure
indication on outcomes of both open (OR) and percutaneous (PR)
revascularization.
Methods: Retrospective review of all consecutive renal artery interventions
performed from January 1, 2002 to December 31, 2006 was conducted. OR
patients were included for analysis only if independent renovascular indica-
tions for revascularization existed.
Results: Forty-seven OR and 203 PR (97% stent) patients were treated with
98% initial technical success. Patients with OR were younger (65  11 vs
72  9; P < .01), on more blood pressure (BP) medications (2.3  1.2 vs
1.8  1.2; P < .05), had more peripheral arterial disease (75% vs 37%;
P < .01), and higher baseline creatinine (2.2  1.6 mg% vs 1.8  1 mg%;
P < .05). Indications for PR were HTN in 46% and RS in 54%, and indications
for OR were HTN in 51% and RS in 49% of cases. PR was unilateral in 169
(83%) and bilateral in 44/203 (17%). OR consisted of bypass in 26 (53%)
and endarterectomy in 21/47 (47%) with 20 (43%) bilateral procedures.
Peri-procedural complications were different (P < .01) and more frequent
in OR (23% vs 12%). Survival was similar at three years (72%  4% PR vs
71%  9% OR; P Z .9). Assisted patency was similar (P Z .6) at one
(94%  2% PR vs 97%  3% OR) and three years (90%  3% PR vs 91% 
5% OR). One year (97%  1% PR vs 97%  3% OR) and three year (93% 
3% PR vs 91%  7% OR) freedom from reintervention was similar
(P Z .8). Clinical outcomes showed patients with OR and PR having similar
rates of cure or improvement in BP (76% PR vs 90% OR; P Z .1) and favored
OR with stable or improved renal function (97% vs 89%; P < .01) by the first
postoperative visit. Hypertension control remained similar (P Z .2) in both
groups with cure/improvement in BP in 74% of PR and 89% of OR patients
at one year. OR remained durable in regards to renal salvage with 52% of
OR patients having improved renal function compared with 24% of PR
(P < .01) patients at one year. At one year, BP control was achieved if
treatment indication was HTN in 100% (18/18) of OR patients and 74%
(46/63) (P Z .04) of those having PR. Renal function stabilized or improved
in 16/19 (85%) of OR and 70/81 (86%) of PR patients when performed for RS
(P Z .4).
Conclusions: PR and OR are similarly efficacious for treatment of HTN asso-
ciated with renal artery stenosis. While immediate and long-term outcomes
favor OR for RS, this may impart from the triage of patients more likely to
benefit from renal artery revascularization to OR.
Open versus endovascular revascularization for chronic mesenteric
ischemia: Risk-stratified outcomes
Gustavo S. Oderich, Thomas C. Bower, Timothy M. Sullivan, Haraldur
Bjarnason, Stephen Cha, Peter Gloviczki
Objective: Outcomes of open (OR) and endovascular revascularization (ER)
for chronic mesenteric ischemia (CMI) were analyzed with respect to clinical
risk stratification.
Methods: The data of 229 consecutive patients treated for CMI with OR
(146 patients/265 vessels) or ER (83 patients/105 vessels) between 1991
and 2005 were reviewed. Patients were classified as low-risk or high-risk
using standard scoring systems. End points were mortality and morbidity,
recurrence-free survival, and patency rates. A subset analysis compared
111 patients (208 vessels) who had OR with 58 patients (76 vessels) who
had stenting.
Results: The ER patients were significantly older (71  15 vs 65  11 years;
P < .05), had higher risk (58% vs 31%), and fewer vessels were revascularized
(1.3  0.5 vs 1.8  0.4). Four (2.7%) procedurally related deaths occurred in
the OR and two (2.4%) in the ER group (P Z NS). Mortality was higher for
high-risk patients (OR, 6.7% vs 0.9%; ER, 4.8% vs 0%; P < .05), but differences
were not significant among low-risk or high-risk OR vs ER patients. OR
patients had more complications (36% vs 18%; P < .001) and longer hospital-
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recurrence-free survival (89%  4% vs 51%  9%), and primary (88%  3% vs
41%  9%) and secondary patency rates (97%  2% vs 88%  4%). More rest-
enoses (hazard ratio [HR], 5.1; 95% confidence interval [CI], 2.4-10.2), recur-
rences (HR, 6.7; 95% CI, 3.3-13.8), and reinterventions occurred in the ER
group (HR, 4.3; 95% CI, 1.9-9.7). At last follow-up, significant symptom
improvement was noted in 137 OR (96%) and 72 ER patients (92%, P Z NS).
In the subset analysis of patients having first-time operations vs stenting,
OR resulted in improved (P < .05) recurrence-free survival (91%  3% vs
56%  8% at 5 years) and better primary and secondary patency rates (93%
 2% and 98%  1% vs 52%  8% and 93%  4% at 3 years).
Conclusion: OR has similar mortality but higher morbidity and longer hospi-
talization than ER in low-risk or high-risk patients with CMI. Both treatments
effectively improved symptoms, but restenosis, recurrent symptoms, and re-
interventions were more likely in ER patients. These findings may guide
treatment selection and counseling of low-risk and high-risk CMI patients
undergoing OR or ER procedures.
Predictors of shunt during carotid endarterectomy with routine
electroencephalography monitoring
Tze-Woei Tan, Manuel Garcia-Toca, Edward J. Marcaccio Jr, Wilfred I.
Carney Jr, Jason T. Machan, Jeffrey M. Slaiby
Background: The routine use of intraoperative electroencephalography
(EEG) monitoring with selective shunting during carotid endarterectomy
(CEA) has been shown to be safe and effective. We attempt to identify
the anatomic and clinical factors associated with significant EEG changes
requiring shunt placement during CEA.
Methods: Between January 2005 and June 2007, 242 CEAs were performed
with selective shunt placement for significant EEG changes. Risk factors as-
sessed include severity of both ipsilateral and contralateral disease, pres-
ence of ipsilateral preoperative symptoms, hypertension, coronary artery
disease, diabetes, age, gender, and preemptive intraoperative blood pres-
sure manipulation to  20% above baseline before cross-clamping. Data were
analyzed with the c2 test (P < .05 was significant).
Results: CEA was performed for asymptomatic disease in 177 of 242 patients
(73.1%). The perioperative stroke rate was 0.8% (2 of 242), and the overall
morbidity rate was 4.5%. No patients died. Significant EEG changes requiring
shunt occurred in 35 patients (14.46%). Factors associated with carotid shunt
placement were moderate ipsilateral carotid artery stenosis (50% to 79%)
compared with severe ( 80%) disease (30.6% vs 11.7%, PZ .003) and degree
of contralateral carotid stenosis (0% to 49%, 10.8%; 50% to 79%, 10.9%; 80% to
99%, 23.2%; occlusion, 50%; PZ .0003). Presence of symptoms, gender, age,
hypertension, diabetes, or coronary artery disease, and preemptive intrao-
perative manipulation of blood pressure were not significant predictors of
shunt placement.
Conclusion: CEA performed with routine EEG monitoring and selective shunt
placement is associated with a low risk of perioperative stroke. Identified
predictors of significant EEG changes were anatomic factors including degree
of contralateral carotid artery disease andmoderate ipsilateral carotid artery
stenosis (50% to 79%). Although contralateral carotid occlusion has been
accepted as indication for shunt placement in the absence of cerebral moni-
toring, this study suggests that high-grade contralateral disease and
moderate ipsilateral carotid stenosis are associated with cerebral ischemia
resulting in EEG changes and should prompt consideration for nonselective
shunting.
Blunt traumatic aortic injury: Initial experience with endovascular repair
Ali Azizzadeh, Kourosh Keyhani, Charles C. Miller III, Sheila M. Coogan, Hazim
J. Safi, Anthony L. Estrera
Objectives: Endovascular treatment of traumatic aortic injury (TAI) is an
alternative to open repair (OR) in patients with blunt trauma. We report
our initial experience after integration of endovascular repair using thoracic
devices.
Methods: A retrospective review of a prospectively collected institutional
trauma registry was performed. Between September 2005 and November
2008, 71 patients with TAI presented to our institution. Based on imaging,
TAIs were classified into grade 1-4 in severity. These included: grade 1,
intimal tear; grade 2, intramural hematoma; grade 3, aortic pseudoaneurysm;
and grade 4, free rupture. Initial management included resuscitation, blood
pressure control, and treatment of associated injuries. After stabilization,
all patients were considered for thoracic endovascular aortic repair (TEVAR)
using a thoracic device. If contraindicated, candidates underwent OR.
Outcome measures were mortality, stroke, paraplegia, intensive care unit
(ICU), and hospital stay.
Results: The mean age was 39.8 years, with 50 males. The mean injury
severity score (ISS) was 42.6. Nineteen (27%) patients with a mean ISS of
60 died shortly after arrival prior to any vascular intervention. Ten (14%)
patients with grade 1 injuries were managed medically. The remaining 42
(59%) patients with grade 2 and 3 injuries underwent repair. Median interval
between admission and repair was 4.3 days (range, 0-109 days). Fifteen
(21%) patients with a mean ISS of 34.4 underwent OR with no mortality,
stroke, or paraplegia. Twenty-seven (38%) patients with a mean ISS of 36.7
underwent TEVAR with no mortality or paraplegia. One TEVAR patient
suffered a perioperative stroke. Twenty-two patients had a TAG (W.L. Gore
Associates, Flagstaff, Ariz) device. Four patients had a Talent Thoracic (Med-
tronic Vascular, Santa Rosa, Calif), and 1 patient had an Excluder (W.L. Gore)
device. The left subclavian artery was covered in 13 (48%) patients. Patients
who underwent TEVAR were older than those who had OR (47.8 vs 31.1
years, P < .006). The aortic diameter proximal to the injury was larger in
the TEVAR group (24.4 vs 19.6 mm, P < .0001). There was no difference in
the mean ICU or hospital length of stay between the two groups. Mortality
correlated with the ISS score (P < .0001). Median follow-up time was 19.4
months (range, 0-27). Only 56% of the TEVAR patients were fully compliant
with their surveillance imaging protocol.
Conclusion: In this initial experience, the results of TEVAR did not differ
from OR. Long-term follow-up is required to determine the effectiveness
of this treatment strategy. Adherence to follow-up imaging protocols is chal-
lenging in this patient population. Next generation devices will make TEVAR
applicable to a wider range of patients.
The role of proteomic research in vascular disease
Ian Nordon, Ranjeet Brar, Robert Hinchliffe, Gillian Cockerill, Ian Loftus,
Matt Thompson
Arterial diseases including atherosclerosis, intimal hyperplasia, and aneu-
rysms have been shown to be a product of genotype and environment. Gene
expression pathways rely on protein translation to generate target effects.
As a result of alternative splicing and post-translational modifications, one
gene does not code for a single protein but for many. Proteomic studies
allow quantification of these proteins in a biologic system and determination
of altered protein expression in disease. Proteomics is a powerful and ex-
panding field of investigation which in combination with other ‘‘omics’’
may enhance understanding of disease pathophysiology and/or identify
biomarkers of vascular disease. This review describes the methodology of
protein mining and provides an insight into the valuable contributions
already made by proteomics to vascular surgery.
Clinical Relevance: Disease processes classified as genetic are function-
ally proteomic. Equally disease pathophysiology is the result of, or leads
to alternate protein expression. Understanding the proteome will clarify
the pathophysiology of disease. The translation of these findings to clin-
ical practice impacts diagnosis, staging, and treatment of disease
processes. Biomarker discovery will enable earlier diagnosis of unstable
atherosclerotic plaques, it will allow identification of aneurysms more
likely to rupture and stratify risk. Identification of specific end-protein
pathways related to disease will also allow development of pharmaco-
therapeutics capable of inhibiting or reversing vascular diseases. Proteo-
mic research has enormous potential to modulate many aspects of
patient care.
Endovascular treatment of internal iliac artery obstructive disease
Konstantinos P. Donas, Arne Schwindt, Georgios A. Pitoulias, Thomas
Scho¨nefeld, Claudia Basner, Giovanni Torsello
Background: This study evaluated the therapeutic value of endovascular
techniques in patients with buttock claudication caused by stenosis or occlu-
sion of the internal iliac artery.
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Methods: The records of patients with buttock claudication who had under-
gone endovascular treatment for internal iliac artery stenosis or occlusion
were analyzed retrospectively, and any associated arterial lesions,
morbidity, restenosis, or recurrent buttock claudication was noted.
Outcomes were compared with published reports. Iliac artery duplex scans
and aortoiliac angiography were performed to detect and confirm the
internal iliac artery obstructive disease. The iliac duplex scanning surveil-
lance protocol was set at 3, 6, and 12 months and yearly thereafter to detect
eventual restenosis or occlusion.
Results: Between September 2006 and September 2008, 21 consecutive
patients (19 men; mean age, 67 years) with 22 cases of buttock claudication
(1 bilateral localization) underwent percutaneous transluminal angioplasty
alone (14 cases) or additional stent placement in case of elastic recoil
(8 cases). Buttock claudication was associated with impotence, thigh claudi-
cation, or calf claudication in seven patients. The endovascular approach
was successful in all patients, without morbidity or mortality. During a mean
follow-up of 14.7  5.7 months, 50% restenosis occurred in one 80-year-old
patient. The patient had a pain-free walking distance of 110 meters and was
treated conservatively.
Conclusions: To our knowledge, the present study is the largest published
report concerning endoluminal treatment of buttock claudication due to
internal iliac artery obstructive disease. The midterm results are very
encouraging and underscore the value of stent-supported angioplasty as
first-line treatment. The procedure can be repeated should significant rest-
enosis occur and does not compromise the option of surgical repair of the
lesions.
Call to Action to prevent venous thromboembolism
Thomas W. Wakefield, Robert B. McLafferty, Joann M. Lohr, Joseph A.
Caprini, David L. Gillespie, Marc A. Passman, on behalf of the Executive
Committee of the American Venous Forum
Deep venous thrombosis and pulmonary embolism, together called venous
thromboembolism, remain a serious national health problem. Estimates
suggest that over 900,000 cases occur in the United States per year, with
300,000 deaths per year. Because of the significant and serious nature of this
problem, aworkshopwas held inMay of 2006, which resulted in the Acting U.S.
Public Health Service Surgeon General’s call to action to prevent deep vein
thrombosis and pulmonary embolism. On September 15, 2008, Acting Surgeon
General, Rear Admiral Steven K. Galson, MD, MPH, and Elizabeth Nabel, MD,
Director National Heart, Lung, and Blood Institute, announced the Call to
Action. The Call to Action highlights public awareness about the risk factors,
triggering events, and symptoms of venous thrombosis and pulmonary embo-
lism, and encourages the development of evidence based practices for
screening, prevention, diagnosis, and treatment of venous thrombosis and
pulmonary embolism. It is designed to encourage new scientific investigation
in an effort to obtain needed evidence to fill in the gaps of knowledge about
venous thrombosis and pulmonary embolism. This knowledge should be
quickly and easily disseminated to the public and put into practice by health
professionals. The Surgeon General’s Call to Action represents one of themost
important advances in the field of venous thromboembolism and sets the stage
for multidisciplinary efforts to combat this serious national health problem.
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